Metformin Effects on Blood Levels of Myonectin in Polycystic Ovarian Women
Abstract
Background: Polycystic ovary syndrome (PCOS) is a most prevalent endocrine diseases for females of childbearing age, and lead to an ovulatory infertility. It was shown that myonectin may be positively associated with insulin resistance parameters. Objectives: To evaluate serum myonectin levels and to determine the effects of metformin treatment on myonectin levels in patients with polycystic ovary syndrome. Patients and Methods: The Cross-Sectional Study carried out in the Department of Obstetrics and Gynecology Salahdeen general hospital in Tikrit city from 1st November 2022-30th January 2023. Patients diagnosed with PCOs depending based on the Rotterdam criteria. Participants were enrolled after all eligibility criteria were confirmed and informed consent completed. Sixty PCOS patients were selected as the PCOS group, while 30 healthy women matched for age with the PCOS patients were selected as the control group. Only 30 patients of them complete the follow up study and they agree to continue on metformin treatment during three months, the duration of the follow up. They take metformin 850 mg twice daily for three months and provide fasting blood samples on the second day of menstruation before and after treatment. The data collection done through: a designed closed and open-ended questionnaire, by using direct interviewing and Ultrasound examination, Laboratory examination. Myonectin, Luteinizing hormone (LH), Follicular Stimulating Hormone (FSH), and insulin were…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 30 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.